All news

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: T. Rowe Price Investment Management, Inc.

Alpha Vantage · StreetInsider · · AI-summarised by FinFlash

T. Rowe Price Investment Management, Inc. filed an Amendment No. 2 to Schedule 13G regarding its ownership in Vaxcyte Inc. As of September 30, 2026, T. Rowe Price Investment Management, Inc. beneficially owned 14,312,368 shares, representing 9.6% of the common stock. The filing indicates sole voting power over 13,699,251 shares and sole dispositive power over all 14,312,368 shares.

Read original source

PCVX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.